Table 1 Metastases formation in the orthotopic pancreatic cancer xenogeneic and syngeneic model
L3.6pl orthotopic model1 | ||||
|---|---|---|---|---|
Liver metastases | LN metastases | |||
Positive | Negative | Positive | Negative | |
Control (n = 12) | 8 (66.7%) | 4 (33.3%) | 8 (66.7%) | 4 (33.3%) |
INC280 10 mg/kg/d (n = 10) | 5 (50%) | 5 (50%) | 3 (30%) | 7 (70%) |
INC280 20 mg/kg/d (n = 8) | 4 (50%) | 4 (50%) | 2 (25%) | 6 (75%) |
Panc02 orthotopic model 2 | ||||
LN metastases | Ascites | |||
Positive | Negative | Positive | Negative | |
Control (n = 7) | 4 (57.1%) | 3 (42.9%) | 4 (57.1%) | 3 (42.9%) |
INC280 10 mg/kg/d (n = 7) | 0 | 7 (100%) | 0 | 7 (100%) |
Panc02 orthotopic model 2 | ||||
LN metastases | Ascites | |||
Positive | Negative | Positive | Negative | |
Control (n = 9) | 6 (66.7%) | 3 (33.3%) | 3 (33.3%) | 6 (66.7%) |
INC280 (n = 7) | 1 (14.3%) | 6 (85.7%) | 1 (14.3%) | 6 (85.7%) |
gemcitabine (n = 8) | 2 (25%) | 6 (75%) | 2 (25%) | 6 (75%) |
INC280 + gemcitabine (n = 8) | 1 (12.5%) | 7 (87.5%)* | 0 (0%) | 8 (100%) |